Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/S0716-10182013000100021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.
Front Immunol
June 2018
Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States.
A Phase 1b/2a clinical trial of NDV-3A vaccine containing a recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC). We investigated the potential use of anti-Als3p sera as surrogate marker of NDV-3A efficacy. Pre- and post-vaccination sera from subjects who experienced recurrence of vulvovaginal candidiasis (R) vs.
View Article and Find Full Text PDFDevelopment of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism.
J Gen Virol
August 2015
United States Department of Agriculture, U.S. National Poultry Research Center, Agricultural Research Services, 934 College Station Road, Athens, GA, 30605, USA.
In the present study, we developed a novel approach for foreign gene expression by Newcastle disease virus (NDV) from a second ORF through an internal ribosomal entry site (IRES). Six NDV LaSota strain-based recombinant viruses vectoring the IRES and a red fluorescence protein (RFP) gene behind the nucleocapsid (NP), phosphoprotein (P), matrix (M), fusion (F), haemagglutinin-neuraminidase (HN) or large polymerase (L) gene ORF were generated using reverse genetics technology. The insertion of the second ORF slightly attenuated virus pathogenicity, but did not affect ability of the virus to grow.
View Article and Find Full Text PDFMechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.
Proc Natl Acad Sci U S A
December 2014
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095; Divisions of Infectious Diseases and St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; and.
Increasing rates of life-threatening infections and decreasing susceptibility to antibiotics urge development of an effective vaccine targeting Staphylococcus aureus. This study evaluated the efficacy and immunologic mechanisms of a vaccine containing a recombinant glycoprotein antigen (NDV-3) in mouse skin and skin structure infection (SSSI) due to methicillin-resistant S. aureus (MRSA).
View Article and Find Full Text PDFApplying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.
Front Immunol
October 2014
NovaDigm Therapeutics, Inc. , Grand Forks, ND , USA.
Recent perspectives forecast a new paradigm for future "third generation" vaccines based on commonalities found in diverse pathogens or convergent immune defenses to such pathogens. For Staphylococcus aureus, recurring infections and a limited success of vaccines containing S. aureus antigens imply that native antigens induce immune responses insufficient for optimal efficacy.
View Article and Find Full Text PDF[NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults].
Rev Chilena Infectol
February 2013
Facultad de Medicina, Universidad de Chile, Chile.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!